CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The NeutroFlow project aims to develop a non-invasive blood test to predict the effectiveness of cancer immunotherapy. By measuring a specific type of neutrophil in the blood, the test seeks to improve patient selection for treatment and reduce unnecessary costs and side effects.
The recent introduction of cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has revolutionised the treatment landscape for a broad range of cancer types.
However, response to ICIs varies widely between patients, with the majority experiencing resistance to therapy.
Moreover, the increasing use of these costly drugs coupled with management of ICI-related toxicities creates a substantial economic burden.
Current biomarker tests for determining eligibility for ICIs have limited pre…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Italy, Milano
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Germany, Heidelberg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Sevilla
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
